Remdesivir and COVID-19: A Systematic Review of Efficacy

As the COVID-19 pandemic unfolded, the urgent need for effective antiviral therapies drove extensive research into existing and novel treatments. Remdesivir, a broad-spectrum antiviral, emerged as a potential candidate. A recent systematic review, published in the Indian Journal of Pharmacology in February 2026, assessed the efficacy of remdesivir in treating COVID-19. This article summarizes the key findings of that review, providing an evidence-based overview of the drug’s impact on clinical outcomes.

Study Methodology and Findings

Researchers conducted a systematic review of clinical trials investigating remdesivir for COVID-19, searching three electronic databases to identify relevant studies. The review included five trials encompassing a total of 13,558 participants. The analysis revealed that, compared to standard care, remdesivir was associated with a 10% increase in the rate of clinical improvement at two weeks (risk ratio: 1.10; 95% confidence interval: 1.04-1.18).

the time to clinical recovery was shorter in patients receiving remdesivir compared to those receiving standard care. While the mortality rate was lower in the remdesivir group at two weeks post-randomization, this difference was not sustained at four weeks. Importantly, extending the duration of remdesivir treatment from 5 days to 10 days did not demonstrate improved efficacy and was linked to a higher risk of adverse events.

Key Takeaways

• Remdesivir may modestly improve recovery time and the rate of clinical improvement in patients with COVID-19.
• The benefit of remdesivir on mortality appears limited, with no significant difference observed at four weeks.
• Prolonging remdesivir treatment beyond five days does not enhance efficacy and may increase the risk of side effects.

Implications for Clinical Practice

The findings suggest that remdesivir can be a useful adjunct to standard care for COVID-19, particularly in the early stages of the illness. Yet, clinicians should carefully weigh the potential benefits against the risks, considering the limited impact on long-term mortality and the potential for adverse events with prolonged use. Further research may be needed to identify specific patient populations who are most likely to benefit from remdesivir therapy.

Sources and Further Information

This article is based on research published in the Indian Journal of Pharmacology (February 2026). For more information on COVID-19, please refer to the World Health Organization Coronavirus Disease (COVID-19) Dashboard.